Conexeu Sciences Inc. (CNXU)
| Market Cap | 106.34M |
| Revenue (ttm) | n/a |
| Net Income | -13.63M |
| EPS | -0.63 |
| Shares Out | 28.21M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 179,458 |
| Open | 3.890 |
| Previous Close | 3.890 |
| Day's Range | 3.685 - 3.897 |
| 52-Week Range | 3.700 - 18.792 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Feb 3, 2027 |
About CNXU
Conexeu Sciences Inc. develops collagen-based regenerative tissue scaffold products for applications in medical aesthetics and tissue repair. The company provides patented collagen-based scaffold products, including a collagen extracellular matrix (ECM) scaffold platform for use in medical aesthetics, wound care, tissue repair, facial rejuvenation, and large-volume body contouring such as face, breast, and butt volume restoration. Its CXU collagen gel is an investigational product targeting therapeutic and aesthetic indications, supporting tiss... [Read more]
Financial Performance
Financial StatementsNews
Conexeu Sciences Quarterly report: Q3 2026
Conexeu Sciences has published its Q3 2026 quarterly earnings report on September 14, 2026.
Conexeu Sciences Sets September and October 2026 Conference Schedule
RENO, Nev., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Conexeu Sciences Inc. (Nasdaq: CNXU) (“Conexeu” or the “Company”), a preclinical-stage biotechnology company advancing an investigational tissue-restorat...
Conexeu Sciences Sees a New Category Forming in Medical Aesthetics as Research Turns to Regeneration
Peer-reviewed research points to the extracellular matrix, the framework that holds tissue together, as central to that work. More than a decade of research has gone into Conexeu's CXU™ Platform
Conexeu to Present at 2026 Controversies & Conversations in Laser & Cosmetic Surgery Symposium on the Role of the Extracellular Matrix in Tissue Regeneration
RENO, Nev., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Conexeu Sciences Inc. (Nasdaq: CNXU) ("Conexeu" or the "Company"), a preclinical-stage biotechnology company advancing an investigational tissue-restorati...
The GLP-1s Are Creating Another Boom, a New $2 Billion Opportunity Exists in Aesthetics. Conexeu Is Building for It
Highlights An unclaimed opportunity. Large-volume body contouring, and restoration of the breasts, hips, and buttocks is a significant injectable aesthetics category yet to be claimed.
A $190 Billion Weight-Loss Boom Has Exposed a Tissue-Restoration Gap Today's Injectables Were Not Built to Fill
Study Highlights P.R.O.O.F study complete, marking an important catalyst. Conexeu has completed its P.R.O.O.F (Performance and Regeneration Outcomes of Flowable Collagen) preclinical program, which pr...
Conexeu Sciences Opens Vancouver R&D Facility to Advance Regenerative Tissue Platform
Nasdaq-Listed Biotech Pioneer Among the First Companies to Operate at adMare's New M4 Innovation Centre Nasdaq-Listed Biotech Pioneer Among the First Companies to Operate at adMare's New M4 Innovation...
Conexeu Sciences initiated with a Buy at H.C. Wainwright
H.C. Wainwright initiated coverage of Conexeu Sciences (CNXU) with a Buy rating and $20 price target Conexeu is a pre-commercial-stage regenerative medicine company, and its lead asset, CXU, is a…
Conexeu Sciences appoints David Bogart as chief commercial officer
Conexeu Sciences (CNXU) announced the appointment of co-founder and director David Bogart as chief commercial officer.
Conexeu Expands Board, Executive, and Advisory Leadership With Five Appointments Post Nasdaq Listing
Board expansion from six to nine directors and the appointment of a Chief Commercial Officer and an advisory board member to help accelerate growth and strengthen execution Board expansion from six to...
Conexeu Sciences Quarterly report: Q2 2026
Conexeu Sciences has published its Q2 2026 quarterly earnings report on June 15, 2026.
Conexeu Sciences provides update on manufacturing scale up for wound care device
Conexeu Sciences (CNXU) announced progress in manufacturing scale up and standardized formulation methods with its contract development and manufacturing organization for its CXU wound care device can...
Conexeu Sciences Reports Manufacturing Scale Up and Regulatory Progress for Lead CXU™ Wound Care Program
Activities are intended to support regulatory testing and the Company's planned first-quarter 2027 FDA 510(k) premarket notification submission Activities are intended to support regulatory testing an...
Conexeu Sciences to Ring Nasdaq Bell on June 10, 2026
RENO, Nev., June 03, 2026 (GLOBE NEWSWIRE) -- Conexeu Sciences Inc. (Nasdaq: CNXU) ("Conexeu" or the "Company"), a biotechnology company advancing tissue regeneration, will ring the Nasdaq Closing Bel...
UPDATE - Conexeu Sciences Initiates Preclinical Development Program for B.R.E.A.S.T.™ Bioregenerative Matrix Platform with Wake Forest Institute for Regenerative Medicine
Conexeu to leverage WFIRM's advanced tissue-organ bioprinting infrastructure to evaluate the durability, integration, and resorbability of proprietary CXU™ 3D-printed matrix technology Conexeu to leve...
Conexeu Sciences Initiates Preclinical Development Program for B.R.E.A.S.T.™ Bioregenerative Matrix Platform with Wake Forest Institute for Regenerative Medicine
Conexeu to leverage WFIRM's advanced tissue-organ bioprinting infrastructure to evaluate the durability, integration, and resorbability of proprietary CXU™ 3D-printed matrix technology Conexeu to leve...
Conexeu Sciences Commences Trading on Nasdaq Under Ticker Symbol "CNXU"
Public listing marks key milestone as Conexeu advances proprietary CXU(TM) platform and vision for regenerative medicine focused on biological restoration Reno, Nevada--(Newsfile Corp. - May 21, 2026)...
Conexeu Sciences opens at $13.50 after Nasdaq direct listing
Conexeu Sciences (CNXU), a preclinical developer of a regenerative tissue device for wound care and aesthetics, filed a resale prospectus with the SEC stating that it expects its common stock…